Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to full health”.
In its midyear outlook report, the firm stated that US pharma and life sciences deal value in Q1 2026 surpassed $65bn, marking the strongest quarter since pandemic-related highs in 2020. PwC’s analysts state this was buoyed by a surge in deals surpassing the billion-dollar ceiling as pharma companies look to differentiate their pipelines with modalities such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), RNA therapeutics, and antibody-drug conjugates (ADCs).
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the PwC team, the main driver behind this surge is the ongoing patent cliff – the largest loss of exclusivity (LOE) off-ramps ever to hit the industry. According to GlobalData, the share of global drug sales under patent protection will only be 4% in 2030, compared to 12% in 2022.
PwC puts the amount of branded pharma revenue exposed at more than $300bn, forcing pharma companies either to accelerate in-house R&D or look elsewhere for pipeline additions.
The firm’s analysts comment that focused and bespoke mid-cap biotech and bolt-on transactions “remain the sweet spot” for the biopharma M&A market.
No drugmaker has perhaps encapsulated this idea more so far this year than Eli Lilly. With healthy amounts of cash at hand courtesy of burgeoning sales for its weight loss drugs, Lilly has undertaken an extensive M&A strategy in 2026. In total, the company has so far bought 10 companies this year. The most expensive of these was the $7.8bn deal to buy sleep drug biotech Centessa at the beginning of January.
In a statement accompanying the report, Roel van den Akker, principal US pharmaceutical & life sciences deals leader at PwC, said: “Biopharma M&A has entered a new phase driven less by scale and more by precision science. We expect M&A to remain strong through year-end as large caps close LOE gaps.”
The resurgence of the biopharma industry’s financial side comes despite upheaval in geopolitical arenas. Most Favored Nation (MFN) drug pricing frameworks, tariff threats on pharmaceutical imports, and Inflation Reduction Act (IRA) negotiation expansions are all shaping transaction strategy.
Q2 follows suit as biopharma deals continue
PwC’s report only analyses Q1, but Q2 showcases that M&A momentum is showing no signs of slowing. The two largest deals in pharma came in the latter quarter – Sun Pharma’s $11.75bn takeover of Organon and GSK’s $10.6bn acquisition of cancer specialist Nuvalent in April and June, respectively.
For the year ahead, the team outlines that urgency to bolster pipelines will remain a key driver.
“Large-cap pharma is likely to remain in active portfolio-replenishment mode. Deal activity continues to concentrate around high-growth, strong-margin therapeutic areas – cardiometabolic and obesity, immunology and inflammation, oncology, and rare disease – while radiopharmaceuticals and RNA medicines also continue to command a premium.”
The uptick in M&A has also gone hand-in-hand with a resurgent initial public offering (IPO) window. Earlier this month, Parabilis Medicines secured the largest IPO in biotech history when it listed on the Nasdaq with $670m in proceeds. Parabilis’ IPO came just two months after Kailera Therapeutics – a biotech developing obesity therapies – secured $625m in a US listing. At the time, this was the largest IPO in biotech history, meaning the record has been broken twice in as many months.
PwC analysts said that tighter exit strategies for biotechs still exist, which will continue to be a factor in M&A for the rest of the year.
“While the biotech IPO window is slowly opening again, there are still only a small number of companies making their debut on the public market. IPOs are requiring increased proof of clinical success, making many biotechs seek alternative exits,” the report says.
However, the report states that those who have made the public jump are doing well with favourable valuations, signalling renewed investor confidence. The influx of capital, too, is helping propel pipelines towards late-stage development.
The report added: “As a result, more advanced assets are driving higher deal values and volumes as large-cap buyers are willing to pay more for derisked assets that address looming LOE gaps.”
